Fabrizio Montecucco1,2,3, Luca Liberale1, Aldo Bonaventura1, Alessandra Vecchiè1, Franco Dallegri1,2, Federico Carbone4. 1. First Clinic of Internal Medicine, Department of Internal Medicine and Medical Specialties, University of Genoa, 6 viale Benedetto XV, 16132, Genoa, Italy. 2. IRCCS AOU San Martino-IST, Genova, 10 Largo Benzi, 16132, Genoa, Italy. 3. Centre of Excellence for Biomedical Research (CEBR), University of Genoa, 9 viale Benedetto XV, 16132, Genoa, Italy. 4. First Clinic of Internal Medicine, Department of Internal Medicine and Medical Specialties, University of Genoa, 6 viale Benedetto XV, 16132, Genoa, Italy. federico.carbone@edu.unige.it.
Abstract
PURPOSE OF REVIEW: The aim of this review is to update the pathophysiological role of innate immune response in the cardiovascular (CV) disease outcomes, particularly focusing on coronary atherosclerosis and heart failure. RECENT FINDINGS: Inflammatory processes comprised with the innate immunity reaction are believed to actively trigger CV disease development and final clinical events. For instance, by releasing proteases and neutrophil extracellular traps, neutrophil recruitment and activation might strongly influence atherosclerotic plaque stability. Similarly, neutrophils drive the early inflammatory response following a myocardial infarction. However, these cells contribute themselves to infarct healing by orchestrating monocyte/macrophage recruitment and polarization within the ischemic myocardium. Given their heterogeneity and plasticity, the balance between recruitment, proliferation, and polarization of monocyte/macrophage is a further leading determinant of advanced plaque maturation. Moreover, timely shift from a pro-inflammatory to a resolving macrophage phenotype may influence cardiac remodeling as well as development of heart failure (HF). Alongside macrophage recruitment and activation into the remote, non-ischemic myocardium also contributes to cardiac remodeling and HF development. Innate immune response is a tightly regulated process where a timely modulation of the balance between damaging and resolving properties critically impacts on CV outcome. Further progress may improve the determination of the prognostic relevance of inflammatory biomarkers on clinical CV outcome.
PURPOSE OF REVIEW: The aim of this review is to update the pathophysiological role of innate immune response in the cardiovascular (CV) disease outcomes, particularly focusing on coronary atherosclerosis and heart failure. RECENT FINDINGS: Inflammatory processes comprised with the innate immunity reaction are believed to actively trigger CV disease development and final clinical events. For instance, by releasing proteases and neutrophil extracellular traps, neutrophil recruitment and activation might strongly influence atherosclerotic plaque stability. Similarly, neutrophils drive the early inflammatory response following a myocardial infarction. However, these cells contribute themselves to infarct healing by orchestrating monocyte/macrophage recruitment and polarization within the ischemic myocardium. Given their heterogeneity and plasticity, the balance between recruitment, proliferation, and polarization of monocyte/macrophage is a further leading determinant of advanced plaque maturation. Moreover, timely shift from a pro-inflammatory to a resolving macrophage phenotype may influence cardiac remodeling as well as development of heart failure (HF). Alongside macrophage recruitment and activation into the remote, non-ischemic myocardium also contributes to cardiac remodeling and HF development. Innate immune response is a tightly regulated process where a timely modulation of the balance between damaging and resolving properties critically impacts on CV outcome. Further progress may improve the determination of the prognostic relevance of inflammatory biomarkers on clinical CV outcome.
Authors: Elke Marsch; Thomas L Theelen; Jasper A F Demandt; Mike Jeurissen; Mathijs van Gink; Robin Verjans; Anique Janssen; Jack P Cleutjens; Steven J R Meex; Marjo M Donners; Guido R Haenen; Casper G Schalkwijk; Ludwig J Dubois; Philippe Lambin; Ziad Mallat; Marion J Gijbels; Johan W M Heemskerk; Edward A Fisher; Erik A L Biessen; Ben J Janssen; Mat J A P Daemen; Judith C Sluimer Journal: Arterioscler Thromb Vasc Biol Date: 2014-09-25 Impact factor: 8.311
Authors: Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Nicolle L Patterson; Manishabrata Bhowmick; Elizabeth R Flynn; Majdouline Asher; Presley L Cannon; Kristine Y Deleon-Pennell; Gregg B Fields; Merry L Lindsey Journal: J Mol Cell Cardiol Date: 2016-10-13 Impact factor: 5.000
Authors: Baris Gencer; Fabrizio Montecucco; David Nanchen; Federico Carbone; Roland Klingenberg; Nicolas Vuilleumier; Soheila Aghlmandi; Dik Heg; Lorenz Räber; Reto Auer; Peter Jüni; Stephan Windecker; Thomas F Lüscher; Christian M Matter; Nicolas Rodondi; François Mach Journal: Eur Heart J Date: 2015-12-09 Impact factor: 29.983
Authors: Fernanda Ornellas; Isabele Bringhenti; Brenda Akemi N F Mattos; Carlos Alberto Mandarim-de-Lacerda; Marcia Barbosa Aguila Journal: Eur J Nutr Date: 2017-05-22 Impact factor: 5.614
Authors: Philip F Halloran; Jeff Reeve; Arezu Z Aliabadi; Martin Cadeiras; Marisa G Crespo-Leiro; Mario Deng; Eugene C Depasquale; Johannes Goekler; Xavier Jouven; Daniel H Kim; Jon Kobashigawa; Alexandre Loupy; Peter Macdonald; Luciano Potena; Andreas Zuckermann; Michael D Parkes Journal: JCI Insight Date: 2018-10-18
Authors: Ana B Arroyo; María P Fernández-Pérez; Alberto Del Monte; Sonia Águila; Raúl Méndez; Rebecca Hernández-Antolín; Nuria García-Barber; Ascensión M de Los Reyes-García; Paula González-Jiménez; María I Arcas; Vicente Vicente; Rosario Menéndez; Vicente Andrés; Rocío González-Conejero; Constantino Martínez Journal: Haematologica Date: 2021-06-01 Impact factor: 9.941
Authors: Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago Journal: Front Physiol Date: 2017-08-18 Impact factor: 4.566